Jeevan Scientific Technology Ltd Reports Strong Quarterly Financial Turnaround

Quarterly Financial Performance Surges

In the December 2025 quarter, Jeevan Scientific Technology Ltd recorded net sales of ₹19.07 crores, the highest quarterly figure on record for the company. This represents a significant improvement compared to the previous quarters, where sales growth had been largely stagnant. The positive momentum is further reflected in the company’s PBDIT (Profit Before Depreciation, Interest and Taxes), which reached ₹5.23 crores, also a record high for the quarter.

The operating profit margin, calculated as operating profit to net sales, expanded to 27.43%, marking the strongest margin performance in recent quarters. This margin expansion indicates improved cost control and operational leverage, which is critical in the competitive healthcare services sector.

Profit before tax (PBT) less other income stood at ₹3.09 crores, while the net profit after tax (PAT) was ₹1.42 crores, both representing peak quarterly figures. Earnings per share (EPS) also rose to ₹0.90, the highest quarterly EPS recorded by the company, signalling enhanced shareholder value creation.

Financial Trend Shift: From Flat to Positive

Jeevan Scientific Technology’s financial trend score has improved markedly, moving from a negative score of -4 three months ago to a positive 15 in the latest quarter. This shift underscores a fundamental change in the company’s financial trajectory, driven by stronger sales and profitability metrics. The company’s mojo score currently stands at 39.0, with a mojo grade of ‘Sell’, upgraded from a previous ‘Strong Sell’ rating as of 1 April 2025. This upgrade reflects the improved financial health and operational performance, although the grade suggests caution remains warranted.

Despite the positive quarterly results, some operational challenges persist. The inventory turnover ratio for the half-year period is at a low 18.86 times, indicating slower movement of stock compared to industry benchmarks. Similarly, the debtors turnover ratio is at 2.56 times, which is relatively low and may point to elongated receivables collection cycles. These factors could impact working capital efficiency and cash flow management going forward.

Stock Price and Market Performance

Jeevan Scientific Technology’s stock price closed at ₹70.01 on 12 February 2026, up 1.10% from the previous close of ₹69.25. The stock traded within a range of ₹69.85 to ₹70.63 during the day, remaining below its 52-week high of ₹76.99 but well above the 52-week low of ₹32.85. This price movement reflects investor optimism following the strong quarterly results.

When compared to the broader market, the stock has outperformed the Sensex across multiple time horizons. Year-to-date, the stock has gained 8.61%, while the Sensex has declined by 1.16%. Over the past year, Jeevan Scientific Technology’s stock has surged by 80.81%, significantly outperforming the Sensex’s 10.41% gain. However, over longer periods such as five and ten years, the stock’s returns of 2.13% and 80.44% respectively lag behind the Sensex’s 63.46% and 267.00% returns, indicating mixed long-term performance.

Sector Context and Competitive Positioning

Operating within the healthcare services sector, Jeevan Scientific Technology faces intense competition and regulatory scrutiny. The sector has witnessed steady demand growth driven by rising healthcare awareness and increased expenditure. Jeevan’s recent financial improvements suggest it is capitalising on these sector tailwinds, improving operational efficiencies and expanding its market share.

However, the company’s mojo grade of ‘Sell’ with a score of 39.0 indicates that while recent quarterly results are encouraging, investors should remain cautious. The company’s market capitalisation grade is 4, reflecting a mid-tier valuation relative to peers. The upgrade from ‘Strong Sell’ to ‘Sell’ signals that the company is on a recovery path but has yet to fully convince the market of sustained growth prospects.

Operational Challenges and Risks

Despite the positive quarterly earnings, Jeevan Scientific Technology’s operational metrics reveal areas of concern. The low inventory turnover ratio of 18.86 times for the half-year period suggests inventory management inefficiencies, which could tie up capital and increase holding costs. Similarly, the debtors turnover ratio of 2.56 times indicates slower collection of receivables, potentially impacting liquidity.

These factors, if not addressed, could constrain the company’s ability to maintain margin expansion and fund growth initiatives. Investors should monitor these ratios closely in upcoming quarters to assess whether operational improvements are sustainable.

Outlook and Investor Considerations

Jeevan Scientific Technology Ltd’s recent quarterly performance marks a significant improvement in its financial health, with record net sales, profit margins, and earnings per share. The positive shift in the financial trend score from negative to positive is a key indicator of operational turnaround. However, the company’s mojo grade of ‘Sell’ and ongoing challenges in inventory and debtor management suggest that investors should exercise prudence.

Comparatively, the stock has outperformed the Sensex in the short to medium term, but long-term returns remain modest relative to the broader market. Investors should weigh the company’s recent growth against sector dynamics and operational risks before making investment decisions.

Continued monitoring of quarterly results and operational metrics will be essential to determine if Jeevan Scientific Technology can sustain its positive momentum and improve its market standing further.

Unlock special upgrade rates for a limited period. Start Saving Now →